{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:15:14Z","timestamp":1787314514492,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.leukres.2023.107353","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T20:43:42Z","timestamp":1689021822000},"page":"107353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database"],"prefix":"10.1016","volume":"132","author":[{"given":"Andrew M.","family":"Brunner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9037-8140","authenticated-orcid":false,"given":"David","family":"Huggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronda","family":"Copher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam L.","family":"Zichlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Downes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"McBride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2023.107353_bib1","unstructured":"National Cancer Institute: Surveillance Epidemiology and End Results Program, Cancer Stat Facts: leukemia \u2014 acute myeloid leukemia (AML). https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html (Accessed 30 September 2021)."},{"issue":"5","key":"10.1016\/j.leukres.2023.107353_bib2","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.clml.2019.11.007","article-title":"Defining acute myeloid leukemia ontogeny in older patients","volume":"20","author":"Melody","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"15","key":"10.1016\/j.leukres.2023.107353_bib3","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1002\/cncr.28129","article-title":"Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades","volume":"119","author":"Thein","year":"2013","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.leukres.2023.107353_bib4","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2217\/fon-2019-0670","article-title":"Acute myeloid leukemia transformed to a targetable disease","volume":"16","author":"Saleh","year":"2020","journal-title":"Future Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2023.107353_bib5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1080\/10428194.2017.1330956","article-title":"Acute myeloid leukemia in the elderly: therapeutic options and choice","volume":"59","author":"Webster","year":"2018","journal-title":"Leuk. Lymphoma"},{"issue":"10","key":"10.1016\/j.leukres.2023.107353_bib6","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/ajh.25214","article-title":"Acute myeloid leukemia: 2019 update on risk-stratification and management","volume":"93","author":"Estey","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2023.107353_bib7","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/asheducation-2009.1.396","article-title":"Optimal induction and post-remission therapy for AML in first remission","author":"Rowe","year":"2009","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"12","key":"10.1016\/j.leukres.2023.107353_bib8","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","article-title":"How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia","volume":"33","author":"Jonas","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107353_bib9","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2023.107353_bib10","first-page":"61908","article-title":"Maintenance therapy in AML","volume":"10","author":"Reville","year":"2020","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.leukres.2023.107353_bib11","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/ajh.25620","article-title":"Maintenance therapy in AML: the past, the present and the future","volume":"94","author":"Molica","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"8","key":"10.1016\/j.leukres.2023.107353_bib12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of relapsed acute myeloid leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"issue":"9","key":"10.1016\/j.leukres.2023.107353_bib13","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/ajh.24780","article-title":"Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: single institution experience","volume":"92","author":"Nanah","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"11","key":"10.1016\/j.leukres.2023.107353_bib14","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1080\/13696998.2018.1513847","article-title":"Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia","volume":"21","author":"Hagiwara","year":"2018","journal-title":"J. Med. Econ."},{"issue":"8","key":"10.1016\/j.leukres.2023.107353_bib15","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1007\/s12325-019-01003-7","article-title":"Economic and clinical burden of relapsed and\/or refractory active treatment episodes in patients with acute myeloid leukemia (AML) in the USA: a retrospective analysis of a commercial payer database","volume":"36","author":"Pandya","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.leukres.2023.107353_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.leukres.2018.06.010","article-title":"Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States","volume":"71","author":"Bell","year":"2018","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.leukres.2023.107353_bib17","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/03007995.2016.1267615","article-title":"Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse","volume":"33","author":"Irish","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"issue":"6","key":"10.1016\/j.leukres.2023.107353_bib18","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1080\/13696998.2018.1425209","article-title":"Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations","volume":"21","author":"Stein","year":"2018","journal-title":"J. Med. Econ."},{"issue":"8","key":"10.1016\/j.leukres.2023.107353_bib19","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/17474086.2019.1627869","article-title":"Healthcare expenses for treatment of acute myeloid leukemia","volume":"12","author":"Bewersdorf","year":"2019","journal-title":"Expert Rev. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2023.107353_bib20","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bbmt.2017.02.017","article-title":"Healthcare costs and utilization for patients age 50 to 64 years with acute myeloid leukemia treated with chemotherapy or with chemotherapy and allogeneic hematopoietic cell transplantation","volume":"23","author":"Preussler","year":"2017","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.leukres.2023.107353_bib21","unstructured":"ResDAC (Research Data Assistance Center), Centers for Medicare & Medicaid Services Cell Size Suppression Policy, 2017. https:\/\/resdac.org\/articles\/cms-cell-size-suppression-policy (Accessed 27 July 2022)."},{"issue":"6","key":"10.1016\/j.leukres.2023.107353_bib22","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am. J. Epidemiol."},{"issue":"23","key":"10.1016\/j.leukres.2023.107353_bib23","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1002\/cncr.32439","article-title":"Temporal patterns and predictors of receiving no active therapy among older patients with acute myeloid leukemia in the United States: a population level analysis","volume":"125","author":"Zeidan","year":"2019","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.leukres.2023.107353_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.blre.2016.09.005","article-title":"Selecting initial treatment of acute myeloid leukaemia in older adults","volume":"31","author":"Podoltsev","year":"2017","journal-title":"Blood Rev."},{"issue":"1","key":"10.1016\/j.leukres.2023.107353_bib25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/cancers12010120","article-title":"Therapeutic choice in older patients with acute myeloid leukemia: a matter of fitness","volume":"12","author":"Palmieri","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.leukres.2023.107353_bib26","first-page":"398","article-title":"Older patients with acute myeloid leukemia: treatment challenges and future directions","volume":"17","author":"Finn","year":"2017","journal-title":"Ochsner J."},{"key":"10.1016\/j.leukres.2023.107353_bib27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/JBM.S279736","article-title":"What does the economic burden of acute myeloid leukemia treatment look like for the next decade? An analysis of key findings, challenges and recommendations","volume":"12","author":"Forsythe","year":"2021","journal-title":"J. Blood Med."},{"issue":"12","key":"10.1016\/j.leukres.2023.107353_bib28","article-title":"Utilization of hematopoietic stem cell transplantation for acute myeloid leukemia and related hospital outcomes: a cross-sectional study of US hospitals","volume":"14","author":"Kommuru","year":"2022","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.leukres.2023.107353_bib29","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.leukres.2023.107353_bib30","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2017-04-778225","article-title":"Racial and ethnic disparities in hematologic malignancies","volume":"130","author":"Kirtane","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2023.107353_bib31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.leukres.2011.10.018","article-title":"Racial differences in presentation, referral and treatment patterns and survival in adult patients with acute myeloid leukemia: a single-institution experience","volume":"36","author":"Bierenbaum","year":"2012","journal-title":"Leuk. Res."},{"issue":"15 Suppl","key":"10.1016\/j.leukres.2023.107353_bib32","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1200\/JCO.2021.39.15_suppl.6523","article-title":"Racial and ethnic enrollment disparities in acute myeloid leukemia clinical trials","volume":"39","author":"Hantel","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2023.107353_bib33","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1158\/2159-8290.CD-20-1579","article-title":"Poor survival and differential impact of genetic features of black patients with acute myeloid leukemia","volume":"11","author":"Bhatnagar","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.leukres.2023.107353_bib34","unstructured":"National Cancer Institute: Surveillance Epidemiology and End Results Program, Cancer statistics by race\/ethnicity https:\/\/seer.cancer.gov\/statistics\/types\/raceethnicity.html (Accessed 30 March 2023)."},{"issue":"11","key":"10.1016\/j.leukres.2023.107353_bib35","first-page":"1831","article-title":"Understanding disparities in leukemia: a national study","volume":"23","author":"Patel","year":"2012","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.leukres.2023.107353_bib36","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2147\/CLEP.S146395","article-title":"Comorbidity index in central cancer registries: the value of hospital discharge data","volume":"9","author":"Lichtensztajn","year":"2017","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.leukres.2023.107353_bib37","unstructured":"National Cancer Institute: Division of Cancer Control & Population Sciences, Measures that are limited or not available in data, 2022 https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/measures.html (Accessed 27 July 2022)."},{"key":"10.1016\/j.leukres.2023.107353_bib38","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:04:33Z","timestamp":1758935073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212623006185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":38,"alternative-id":["S0145212623006185"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107353","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107353","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107353"}}